Human recombinant antibody against Candida [2]

Pediatric Infectious Disease Journal

Volumn 25, Issue 10, 2006, Pages 959-960

  Rowlands, Helen Elizabeth ^a   Morris, Kevin ^a   Graham, Clive ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CEFUROXIME; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; METRONIDAZOLE; MYCOGRAB; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL ABSCESS; ABSCESS DRAINAGE; ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; DEVICE INFECTION; DOWN SYNDROME; FEMALE; FUNGAL VIRULENCE; FUNGUS ISOLATION; FUNGUS SEPSIS; GASTROSTOMY; HUMAN; LETTER; PARENTERAL NUTRITION; PERITONITIS; PHOBIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SCHOOL CHILD; SEPSIS;

ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CHILD; FEMALE; HUMANS; RECOMBINANT PROTEINS;

EID: 33749435589     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000237922.28863.ab     Document Type: Letter

References (2)

1. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial in of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404-1413.
2. Heitman J. A fungal Achilles' heel. Science. 2005;309:2175-2176